Skip to main content

Table 1 Foreshadowed issues and topical questions

From: Evaluating the implementation of health and safety innovations under a regulatory context: A collective case study of Ontario’s safer needle regulation

Foreshadowed Issues:

Does needlestick injury prevention continue to be a priority for organizations?

Are organizations continuing to improve the availability and quality of safety devices and monitoring issues with existing devices?

Are existing goals to eliminate needlestick injuries through the uptake of SEMDs realistic considering device availability and utility?

How have healthcare workers responded to the transition to SEMDs? Is there resistance to the use of these devices among specific groups of workers?

Has the regulation stimulated the uptake of safer engineered devices beyond the regulatory requirements?

Has the transition to SEMDs negatively impacted patient care in any way?

Topical Questions:

Initial implementation procedures and activities:

Was a sharps safety committee established?

Did the process involve inventory review?

What role did manufacturers have in facilitating the implementation process?

Were SEMD pilot tested?

Were workers involved in device selection?

What kind of training and education on SEMD use and needlestick injury prevention was provided?

Are there written policies and procedures in place?

Ongoing procedures and activities for sustained integration:

Are there activities in place to increase compliance with the use of SEMDs?

Is the use of SEMDs monitored? How are issues addressed?

Is there continued training and education on the use of SEMDs and needlestick injury prevention?

Does the original sharps committee still meet?

Are SEMDs beyond the regulatory requirements being considered?

Contextual questions about the transition:

When did the organization start to transition to the use of these devices?

Are there still exceptions to the use of SEMDs?

What do health and safety inspectors look for with regards to compliance with Ontario’s safer needle regulation

Has the joint health and safety committee had a role in the implementation process?

What are the organization’s ongoing health and safety priorities?